Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma

2'-Hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma

(2011) L. D. Nagaprashantha et al.   CARCINOGENESIS

Sorafenib in renal cell carcinoma

(2011) José Ángel Arranz et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics

(2010) Vanessa Rausch et al.   CANCER RESEARCH

Combination Therapy of Interleukin-2 and Sorafenib Improves Survival Benefits and Prevents Spontaneous Pulmonary Metastasis in Murine Renal Cell Carcinoma Models

(2010) Y. Amagai et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma

(2009) Y. Tabe et al.   CLINICAL CANCER RESEARCH

Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor

(2009) H. Huynh et al.   MOLECULAR CANCER THERAPEUTICS

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

(2008) W. L. Dahut et al.   CLINICAL CANCER RESEARCH

Tumor Suppressor Protein p53 Regulates Megakaryocytic Polyploidization and Apoptosis

(2008) Peter G. Fuhrken et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

(2008) Nilofer S. Azad et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2

(2008) L Gu et al.   LEUKEMIA

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells

(2008) T Maimets et al.   ONCOGENE

Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors

(2008) L. Dal Lago et al.   ONCOLOGIST